News | August 09, 2023
Hikal posts Q1 FY 24 consolidated PAT at Rs. 6.92 Cr
US FDA approval is in line with de-risking strategy for additional API site to service our global customer base
US FDA approval is in line with de-risking strategy for additional API site to service our global customer base
The company has reported total income of Rs. 115.37 crores during the period ended June 30, 2023
Sajjan India Limited is looking for expansion, both organically and through acquisitions, to achieve the planned growth
The new lab will enable the Group to accelerate its efforts in this area, building new competencies and capabilities, as well as strengthening Solvay’s ability to develop breakthroughs in biodegradable-by-design solutions.
The consolidated EBITDA stood at Rs. 89.3 crore in FY23 as compared to Rs. 164.5 crore in the same period last year
The acquisition would be by way of a share purchase agreement dated Dec. 26, 2022.
This plant adds around 60,000 MT of capacity, scaling Jubilant Ingrevia Limited’s overall annual Acetic Anhydride capacity to 210,000 MT
This acquisition will boost Neogen's portfolio by offering organolithium derivatives to existing pharma industry
Q2 FY23 business performance has been slow primarily due to lower volume offtake from pharmaceutical manufacturers
The Group will continue to make proactive investments of its management resources in the life science business
Subscribe To Our Newsletter & Stay Updated
